Skip to main content
Back
BPMUF logo

Basilea Pharmaceutica AG

Data quality: 100%
BPMUF
OTC Healthcare Biotechnology
$71.00
$0.00 (0.00%)
Mkt Cap: 871.33M
Day Range
$71.00 $71.00
52-Week Range
$47.50 $74.00
Volume
100
50D / 200D Avg
$67.99 / $62.85
Prev Close
$71.00

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 21.7 0.4
P/B 6.8 2.9
ROE % 38.5 3.8
Net Margin % 17.3 3.9
Rev Growth 5Y % 11.9 10.0
D/E 0.8 0.2

Key Takeaways

Revenue grew 11.93% annually over 5 years — strong growth
Earnings declined -48.17% over the past year
ROE of 38.49% indicates high profitability
Net margin of 17.30% shows strong profitability
Generating 59.50M in free cash flow
Cash machine — converts 147.94% of earnings into free cash flow

Growth

Revenue Growth (5Y)
11.93%
Revenue (1Y)11.49%
Earnings (1Y)-48.17%
FCF Growth (3Y)112.22%

Quality

Return on Equity
38.49%
ROIC16.91%
Net Margin17.30%
Op. Margin22.20%

Safety

Debt / Equity
0.79
Current Ratio5.11
Interest Coverage0.00

Valuation

P/E Ratio
21.66
P/B Ratio6.81
EV/EBITDA18.26
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 11.49% Revenue Growth (3Y) 21.45%
Earnings Growth (1Y) -48.17% Earnings Growth (3Y) 96.17%
Revenue Growth (5Y) 11.93% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 232.51M Net Income (TTM) 40.22M
ROE 38.49% ROA 14.26%
Gross Margin 83.09% Operating Margin 22.20%
Net Margin 17.30% Free Cash Flow (TTM) 59.50M
ROIC 16.91% FCF Growth (3Y) 112.22%
Safety
Debt / Equity 0.79 Current Ratio 5.11
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio 21.66 P/B Ratio 6.81
P/S Ratio 3.75 PEG Ratio -0.31
EV/EBITDA 18.26 Dividend Yield 0.00%
Market Cap 871.33M Enterprise Value 942.65M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 232.51M 208.54M 157.63M 147.77M 148.12M
Net Income 40.22M 77.59M 10.45M 12.15M -6.83M
EPS (Diluted) 3.14 5.83 0.86 1.02 -0.58
Gross Profit 193.19M 169.86M 130.84M 123.16M 124.05M
Operating Income 51.62M 61.18M 19.21M 18.54M 1.19M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 282.13M 257.76M 173.29M 220.85M 247.27M
Total Liabilities 154.13M 176.77M 183.29M 265.86M 305.87M
Shareholders' Equity 128.00M 81.00M -10.00M -45.01M -58.61M
Total Debt 100.98M 111.67M 128.61M 187.14M 218.96M
Cash & Equivalents 29.66M 120.70M 59.90M 84.70M 53.70M
Current Assets 251.85M 220.91M 152.15M 175.36M 241.07M
Current Liabilities 49.24M 45.56M 47.59M 74.85M 174.41M

Strategy Scores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#554 of 1021
43
Custom Capital Light Compounder
#171 of 211
26

Recent Activity

Entered Cash Flow Compounder
Mar 24, 2026
Entered Capital Light Compounder
Mar 24, 2026